[Form 4] Strata Critical Medical, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Strata Critical Medical, Inc. (SRTA) reported insider equity changes by Co‑CEO, General Counsel, and Director Melissa M. Tomkiel. On 10/31/2025, she acquired 208,929 shares of Class A common stock at $0, reflecting certification of performance-based restricted stock units (PSUs). On 11/03/2025, 106,659 shares were disposed under code F at $5.03, representing shares withheld to satisfy tax obligations upon PSU vesting. Following these transactions, she beneficially owns 1,372,642 shares, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tomkiel Melissa M.

(Last) (First) (Middle)

C/O STRATA CRITICAL MEDICAL, INC.

31 HUDSON YARDS, 14TH FLOOR

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Strata Critical Medical, Inc. [ SRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-CEO and General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
10/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A common stock, $0.0001 par value per share	10/31/2025		A		208,929(1)	A	$0	1,479,301	D
Class A common stock, $0.0001 par value per share	11/03/2025		F		106,659(2)	D	$5.03	1,372,642	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that were acquired upon the certification of the Compensation Committee of the Issuer's Board of Directors of the satisfaction of performance criteria underlying an award of performance-based restricted stock units ("PSUs") granted to the Reporting Person on March 8, 2024.

2. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of PSUs.

Remarks:

	/s/ Melissa M. Tomkiel	11/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SRTA disclose on this Form 4?

The company disclosed PSU-related activity: 208,929 shares were acquired at $0 on 10/31/2025, and 106,659 shares were withheld on 11/03/2025 for taxes at $5.03.

Who is the reporting person in SRTA's Form 4 and what is their role?

Melissa M. Tomkiel, who serves as Co‑CEO, General Counsel, and Director of Strata Critical Medical, Inc.

How many SRTA shares does the insider own after the reported transactions?

Following the transactions, the reporting person beneficially owns 1,372,642 Class A shares, held directly.

What does transaction code 'A' signify in this filing?

Code A reflects an acquisition, here tied to certified performance-based RSUs (PSUs) that delivered 208,929 shares at $0.

What does transaction code 'F' indicate for the 11/03/2025 entry?

Code F indicates shares (106,659) withheld by the issuer to cover tax withholding obligations upon PSU vesting, priced at $5.03.

Were any derivative securities reported in this Form 4?

No derivative securities entries were reported in the provided table.

What class of SRTA stock is involved in these transactions?

Class A common stock, $0.0001 par value per share, was involved in both transactions.